|
US2014031404A1
|
|
Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
|
|
CA2818198A1
|
|
Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
|
|
WO2011044370A1
|
|
Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
|
|
WO2009097590A1
|
|
Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
|
|
WO2008144604A1
|
|
Substituted 2-methyl-2-phenoxy-n-propyl-propionamides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity
|
|
AU2007247878A1
|
|
Cannabinoid receptor antagonists/inverse agonists
|
|
AU2007226673A1
|
|
Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
|
|
WO2007008963A1
|
|
Mao-b inhibitors useful for treating obesity
|
|
EP1906952A1
|
|
Mao-b inhibitors useful for treating obesity
|
|
US2007078172A1
|
|
Mao-b inhibitors useful for treating obesity
|
|
CA2620476A1
|
|
Mao-b inhibitors useful for treating obesity
|
